Published January 5, 2017 | Version v1
Journal article

Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system

  • 1. Global Station for Quantum Medical Science and Engineering, Global Institution for Collaborative Research and Education (GI-CoRE), Hokkaido University, Sapporo (Japan)
  • 2. Department of Radiation Oncology, Hokkaido University Hospital, North-14 West-5, Kita-ku, Sapporo (Japan)
  • 3. Department of Radiology and Radiation Oncology, Kitasato University School of Medicine, Sagamihara (Japan)
  • 4. Department of Nuclear Medicine, Fukui Prefectural Hospital, Fukui (Japan)
  • 5. Department of Therapeutic Radiology, Yamaguchi University Graduate School of Medicine, Ube (Japan)
  • 6. Department of Radiation Medicine, Hokkaido University Graduate School of Medicine, Sapporo (Japan)

Description

To investigate the clinical outcomes of stage I and IIA non-small cell lung cancer (NSCLC) patients treated with stereotactic body radiotherapy (SBRT) using a real-time tumor-tracking radiotherapy (RTRT) system. Patterns-of-care in SBRT using RTRT for histologically proven, peripherally located, stage I and IIA NSCLC was retrospectively investigated in four institutions by an identical clinical report format. Patterns-of-outcomes was also investigated in the same manner. From September 2000 to April 2012, 283 patients with 286 tumors were identified. The median age was 78 years (52–90) and the maximum tumor diameters were 9 to 65 mm with a median of 24 mm. The calculated biologically effective dose (10) at the isocenter using the linear-quadratic model was from 66 Gy to 126 Gy with a median of 106 Gy. With a median follow-up period of 28 months (range 0–127), the overall survival rate for the entire group, for stage IA, and for stage IB + IIA was 75%, 79%, and 65% at 2 years, and 64%, 70%, and 50% at 3 years, respectively. In the multivariate analysis, the favorable predictive factor was female for overall survival. There were no differences between the clinical outcomes at the four institutions. Grade 2, 3, 4, and 5 radiation pneumonitis was experienced by 29 (10.2%), 9 (3.2%), 0, and 0 patients. The subgroup analyses revealed that compared to margins from gross tumor volume (GTV) to planning target volume (PTV) ≥ 10 mm, margins < 10 mm did not worsen the overall survival and local control rates, while reducing the risk of radiation pneumonitis. This multi-institutional retrospective study showed that the results were consistent with the recent patterns-of-care and patterns-of-outcome analysis of SBRT. A prospective study will be required to evaluate SBRT using a RTRT system with margins from GTV to PTV < 10mm. The online version of this article (doi:10.1186/s13014-016-0742-3) contains supplementary material, which is available to authorized users.

Availability note (English)

Available from http://dx.doi.org/10.1186/s13014-016-0742-3; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217432

Additional details

Identifiers

Publishing Information

Journal Title
Radiation Oncology (Online)
Journal Volume
12
Journal Page Range
vp.
ISSN
1748-717X

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
49082318
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
GY RANGE 100-1000; GY RANGE 10-100; LUNGS; MULTIVARIATE ANALYSIS; NEOPLASMS; PATIENTS; RADIATION DOSES; RADIATION HAZARDS; RADIOTHERAPY
Descriptors DEC
ABSORBED DOSE RANGE; BODY; DISEASES; DOSES; GY RANGE; HAZARDS; HEALTH HAZARDS; MATHEMATICS; MEDICINE; NUCLEAR MEDICINE; ORGANS; RADIATION DOSE RANGES; RADIOLOGY; RESPIRATORY SYSTEM; STATISTICS; THERAPY

Optional Information

Copyright
Copyright (c) The Author(s). 2017
Notes
PMCID: PMC5217432; PMID: 28057036; PUBLISHER-ID: 742; OAI: oai:pubmedcentral.nih.gov:5217432